Long term survival in a patient with recurrent malignant glioma treated with intratumoral infusion of an IL4-targeted toxin (NBI-3001).

Abstract

Intratumoral infusion of a recombinant targeted toxin (NBI-3001) consisting of the receptor binding domain of human interleukin 4 (IL-4) and Pseudomonas aeruginosa exotoxin A is an investigational treatment for malignant brain tumors. This 27-year-old male patient presented with a recurrent malignant glioma WHO grade IV after surgery and adjuvant radiation and chemotherapy. The recurrence was treated with intratumoral infusion of NBI-3001 at a dose of 9 microg/ml in 66 ml of infusate. Treatment resulted in long-term survival for 3 years after toxin infusion with a durable tumor response. There were some permanent neurological side effects resulting from toxin infusion. The patient eventually died after a late local recurrence of the known brain tumor. Such clinical evolution of a malignant glioma after a single round of immunotoxin infusion is rather unusual. The late local recurrence may suggest that repeated courses rather than a single infusion of intratumoral toxin are possibly needed for successful long-term tumor control.

• Authors: N G Rainov, V Heidecke
• Journal: Journal of neuro-oncology (J Neurooncol) Vol. 66 Issue 1-2 Pg. 197-201 (Jan 2004) ISSN: 0167-594X [Print] United States
• PMID: 15015787 (Publication Type: Case Reports, Journal Article)

Chemical References

• Bacterial Toxins
• Exotoxins
• interleukin-4-Pseudomonas exotoxin
• Interleukin-4

Topics

• Adult
• Bacterial Toxins (administration & dosage, adverse effects)
• Brain Neoplasms (diagnosis, drug therapy, mortality)
• Exotoxins (administration & dosage, adverse effects)
• Glioma (diagnosis, drug therapy)
• Humans
• Injections, Intralesional
• Interleukin-4 (administration & dosage, adverse effects)
• Magnetic Resonance Imaging
• Male